Drug Profile


Alternative Names: BRN 4205979; LY 186641

Latest Information Update: 22 Jan 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics
  • Mechanism of Action Ribonucleoside diphosphate reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 22 Jan 2007 Discontinued - Phase-I for Cancer in USA (PO)
  • 22 Jan 2007 Discontinued - Phase-I for Solid tumours in Denmark (PO)
  • 22 Jan 2001 No-Development-Reported for Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top